Clinical trials: Phase 1b
Pulmonary Tuberculosis
Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers
The purpose of this study is to determine the safety, tolerability, and immunogenicity in BCG-vaccinated healthy adult subjects of an investigational vaccine being developed for the prevention of pulmonary tuberculosis.
- Trial name
- NCT01927159
- Testing
- ID93 + GLA-SE
- Where
- South Africa
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Access to Advanced Health Institute (AAHI)
Healthy
A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants
Single center, double-masked study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Subjects
- Trial name
- NCT07717918
- Testing
- BL1332 eye drops
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Rheumatoid Arthritis RA
Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis
Phase 1b. To evaluate the safety and tolerability of subcutaneous (SC) dose administrations of Efavaleukin alfa in subjects with active rheumatoid arthritis (RA). Phase 2a.
- Trial name
- NCT03410056
- Testing
- Efavaleukin alfa
- Where
- 15 sites in United States, Bulgaria and 3 more
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Amgen
Safety
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects
This Phase 1b study will evaluate the safety of PRV-3279 in healthy adult subjects
- Trial name
- PREVAIL1 (NCT03955666)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Provention Bio, Inc.
SARS-CoV-2
A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults
This study is a Phase I/II clinical study in healthy adults designed to assess the safety, tolerability, and immunogenicity of receiving 2 IM injections of Covigenix VAX-001/-1b, 28 days apart.
- Trial name
- NCT04591184
- Testing
- Covigenix VAX-001
- Where
- 4 sites in Burkina Faso, Canada and 2 more
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Entos Pharmaceuticals Inc.
Leprosy
Trial LEP-F1 + GLA-SE in Healthy Adult in Areas Endemic for Leprosy
This is a phase 1b, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of LEP-F1 + GLA-SE compared to placebo administered as three intramuscular (IM) injections…
- Trial name
- NCT06627257
- Testing
- LepVax (2 μg LEP-F1 + 5 μg GLA-S): Low dose, LepVax (10 μg LEP-F1 + 5 μg GLA-SE): High dose
- Where
- Brazil
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Infections, Vector Borne Diseases
Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum
This is an open-label, adaptive study using the P. falciparum induced blood stage malaria (IBSM) model to characterise the pharmacokinetic/pharmacodynamic (PK/PD) profile and safety of MMV367 (the IMP).
- Conditions
- Infections, Vector Borne Diseases, Systemic Inflammatory Response Syndrome, Inflammation
- Trial name
- NCT05979207
- Testing
- MMV367 3mg, P. falciparum IBSM infection, MMV367 5mg
- Where
- 2 sites in Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Influenza
Influenza Vaccine Challenge Study in Healthy Subjects
The purpose of this research is to study the safety, tolerability and effectiveness of the investigational influenza vaccine in healthy volunteers infected with an attenuated influenza A virus.
- Trial name
- NCT01226758
- Testing
- Influenza vaccine (FLU-v)
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- PepTcell Limited
Atopic Dermatitis, Type 1 Hypersensitivity
Allergic Disease Onset Prevention Study
This is a Phase 1b/2, randomized, double-blind, multi-center study to evaluate the safety, tolerability, and preliminary clinical efficacy of STMC-103H in neonates and infants at risk for developing allergic disease (Type 1…
- Trial name
- adored (NCT05003804)
- Testing
- STMC-103H
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 283 people, healthy volunteers welcome
- Sponsor
- Siolta Therapeutics, Inc.